So-called digital surgery combines robotic instrumentation with computer-aided visualization and decisionmaking, supplementing them with a continuum of outcome data tracking patients before, during and after the procedure.
As the biopharma industry’s digital transformation continues apace, with the rapid acceptance of tools such as artificial intelligence and machine learning, certain projects promise to yield impacts on a much wider scale.
Verily and Ethicon’s robotics joint venture, Verb Surgical, announced Thursday that it unveiled its first digital surgery prototype to its partners at the companies as well as to execs from parent companies Alphabet and Johnson & Johnson.
Johnson & Johnson and Verily launched their joint venture, Verb Surgical, in December 2015, nine months after J&J and what was then Google Life Sciences inked a partnership surrounding robotic surgery.
Verb Surgical is working on what it sees as "Surgery 4.0": the next iteration of surgery that incorporates robotics, advanced visualization, machine learning, data analytics and connectivity.